A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
An estimate of 100,000 ophthalmic appointments have been cancelled by a single hospital (Moorfields, London, UK) over a 3-month duration due to the COVID-19 pandemic. … Read More »Stay-at-home visual evaluations provide an innovative tool for printable visual acuity (VA) charts
Surgical “pearls” of research have been published in the journal, Retina (accessed January 18, 2021), following the completion of 120 subretinal surgeries, performed by a… Read More »Surgical “pearls” point to valuable observations among 120 treatments using subretinal gene therapy for inherited retinal degenerations.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 18th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »January 18th, 2021: “EURETINA-Brief”© Issue No. 228
Genentech (a member of the Roche Group [SIX: RO, ROG; OTCQX: RHHBY]) have announced positive top-line results from two identically designed global Phase III studies,… Read More »Genentech (a subsidiary of Roche) has reported a key non-inferior end-point for faricimab for DME, gearing up for a head-to-head anti-VEGF market
An international consortium of over 80 of the world’s experts in low vision (LV) and ultra low-vision (ULV) in the field of vision restoration has… Read More »Low vision (LV) and ultra low-vision (ULV) assays address several key recommendations on the measurement and reporting of patient outcomes in vision restoration trials
Research on epigenetic transcription factors has shown that a novel study may be applicable for some types of age-related disorders. The cover of Nature, on… Read More »Reprogramming “youthful” epigenetic information shows that restoration of vision in mature eyes may use re-engineered transcription factors
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 4th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »January 4th, 2021: “EURETINA-Brief”© Issue No. 227
A biotechnology company, Neurogene Inc., has raised $115 million in a second-round financing to be used to accelerate clinical trials. A range of treatments for… Read More »A biotechnology company founded by Neurogene Inc. (NY, USA) has raised $115M to focus on rare Batten disease.
Researchers based at the University of Cambridge, UK, have reported intriguing results from a Phase 3 trial for a gene therapy treatment of Leber hereditary… Read More »A “failed” clinical trial study showed improved treatment in LHON patients with results in both study and control eyes